The Potential of Anti-IgE in Food Allergy Therapy

Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-Sponsored expert panel report. Nutr Res. 2011;31:61–75.

Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8:218–30.

Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133:291–307.e295.

Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18:693–704.

MacGlashan DW. IgE-dependent signaling as a therapeutic target for allergies. Trends Pharmacol Sci. 2012;33:502–9.

Syed A, Kohli A, Nadeau KC. Food allergy diagnosis and therapy: where are we now? Immunotherapy. 2013;5:931–44.

Bégin P, Nadeau KC. Diagnosis of food allergy. Pediatr Ann. 2013;42:102–9.

Henson M, Burks AW. The future of food allergy therapeutics. Semin Immunopathol. 2012;34:703–14.

Gupta R, Holdford D, Bilaver L, Dyer A, Holl JL, et al. THe economic impact of childhood food allergy in the united states. JAMA Pediatr. 2013;167:1026–31.

Nadeau KC, Kohli A, Iyengar S, DeKruyff RH, Umetsu DT. Oral immunotherapy and Anti-IgE antibody-adjunctive treatment for food allergy. Immunol Allergy Clin N Am. 2012;32:111–33.

Khoriaty E, Umetsu DT. Oral immunotherapy for food allergy: towards a new horizon. Allergy Asthma Immunol Res. 2013;5:3–15.

Wang J, Sampson H. Oral and sublingual immunotherapy for food allergy. Asian Pac J Allergy Immunol. 2013;31:198–209.

Wang J, Patil SP, Yang N, Ko J, Lee J, et al. Safety, tolerability, and immunologic effects of a food allergy herbal formula in food allergic individuals: a randomized, double-blinded, placebo-controlled, dose escalation, phase 1 study. Ann Allergy Asthma Immunol. 2010;105:75–84.

Patil SP, Wang J, Song Y, Noone S, Yang N, et al. Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: extended phase I study. J Allergy Clin Immunol. 2011;128:1259–65.

Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8:205–17.

Shields R, Whether W, Zioncheck K, O'Connell L, Fendly B, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995;107:308–12.

Kolbinger F, Saldanha J, Hardman N, Bendig MM. Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Eng. 1993;6:971–80.

Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol. 2011;29:209–19.

MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438–45.

Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64:1728–36.

van Neerven RJJ, van Roomen CPAA, Thomas WR, de Boer M, Knol EF, et al. Humanized Anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells. Int Arch Allergy Immunol. 2001;124:400–2.

Segal M, Stokes JR, Casale TB. Anti-Immunoglobulin E therapy. World Allergy Org J. 2008;1:174–83.

Leung DYM, Sampson HA, Yunginger JW, Burks AW, Schneider LC, et al. Effect of Anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:986–93. This is the first study reporting efficacy of anti-IgE (talizumab) in the treatment of food allergy.

Sampson HA, Leung DYM, Burks AW, Lack G, Bahna SL, et al. A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309–10. Although this study has limited data owing to early termination, it serves as the only referene point for a placebo-controlled omalizumab monotherapy trial in treating patients with peanut allergy.

Savage JH, Courneya J-P, Sterba PM, MacGlashan DW, Saini SS, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123–9. This report uncovers interesting kinetic and mechanistic details behind desensitization through omalizumab monotherapy.

MacGlashan Jr DW, Savage JH, Wood RA, Saini SS. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol. 2012;130:1130–5.

Gernez Y, Tirouvanziam R, Yu G, Ghosn EEB, Reshamwala N, et al. Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy. Int Arch Allergy Immunol. 2011;154:318–27.

Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–40.

Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127:1622–4. This is the first open-label pilot study demonstrating efficacy of anti-IgE as an adjunctive therapy with OIT in children with milk allergy.

Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol. 2012;5:267–76. This report represents an excellent reference for understanding the immune mechanism behind anti-IgE + OIT combination therapy.

Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132:1368–74. This report demonstrates efficacy of anti-IgE + OIT combination therapy in treating peanut-allergic children, thus endorsing previous findings from milk study.

Bégin P, Winterroth LC, Dominguez T, Wilson S, Bacal L, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10:1.

Bégin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol. 2014;10:7. This recent open-label phase I study is the first to demonstrate safe and efficeint administration of anti-IgE + OIT combination therapy in simultanous desensitization to multiple food allergens.

Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124:292–300.

Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654–60.

Rachid R, Umetsu D. Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol. 2012;34:689–702.

Smith LD, Leatherbarrow RJ, Spivey AC. Development of small molecules to target the IgE:FcεRI protein–protein interaction in allergies. Future Med Chem. 2013;5:1423–35.

Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem. 2010;285:20850–9.

Kim B, Eggel A, Tarchevskaya SS, Vogel M, Prinz H, et al. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature. 2012;491:613–7.